SCHEMBL14973256

SCHEMBL14973256

Cn1ncc(-c2nc(-c3cnc(N)nc3)no2)c1COc1ccc(C(F)(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 1/20 0.40
PDE2A O00408 1/20 0.39
FFAR1 O14842 1/20 0.39
CHUK O15111 1/20 0.39
TXNRD1 Q16881 1/20 0.39
NOX4 Q9NPH5 1/20 0.39
SPHK2 Q9NRA0 2/20 0.38
STAT3 P40763 2/20 0.38
ADORA2B P29275 2/20 0.38
ADORA1 P30542 2/20 0.38
LMNA P02545 1/20 0.38
THRB P10828 1/20 0.38
POLB P06746 1/20 0.38
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
HSP90AA1 P07900 1/20 0.37
RAB9A P51151 1/20 0.37
S1PR1 P21453 3/20 0.37
ALOX5AP P20292 1/20 0.37
SPHK1 Q9NYA1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14972955 0.92 SMPD1 (0.40) SMPD1PDE2AFFAR1CHUKTXNRD1
SCHEMBL14973124 0.89 CHUK (0.47) SMPD1FFAR1CHUKTXNRD1NOX4
SCHEMBL14973025 0.89 S1PR1 (0.46) SMPD1FFAR1CHUKTXNRD1NOX4
SCHEMBL14973342 0.89 GABRA5 (0.41) PDE2ACHUKTXNRD1NOX4LMNA
SCHEMBL14973304 0.89 LMNA (0.42) SMPD1PDE2AFFAR1CHUKTXNRD1
SCHEMBL14973300 0.88 NR1H4 (0.47) SMPD1FFAR1CHUKTXNRD1NOX4
SCHEMBL14973330 0.88 CHUK (0.48) SMPD1FFAR1CHUKTXNRD1NOX4
SCHEMBL14973249 0.88 CXCR1 (0.46) SMPD1FFAR1CHUKTXNRD1NOX4
SCHEMBL14973380 0.88 S1PR1 (0.46) SMPD1PDE2ASTAT3S1PR1
SCHEMBL14972918 0.88 HDAC1 (0.50) SMPD1FFAR1CHUKTXNRD1NOX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2604602-A1 HETEROARYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-19 EP disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE GRIN2C, GRIN2B, GRIN3A SMPD1 4077/4885PDE2A 2129/4885FFAR1 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.